We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




New Radiotracer Helps Diagnose Prostate Cancer Faster

By MedImaging International staff writers
Posted on 17 Feb 2017
Print article
Image: The new tracer shows tumors in a 64-year-old man with PC (Photo courtesy of NIBIB).
Image: The new tracer shows tumors in a 64-year-old man with PC (Photo courtesy of NIBIB).
A new study describes a radioactive tracer that targets two different biomarkers, gastrin-releasing peptide receptor (GRPR) and integrin αvβ3, which often indicate prostate cancer (PC).

Developed by researchers at Peking Union Medical College Hospital and the U.S. National Institute of Biomedical Imaging and Bioengineering, the new dual-receptor 68Ga-labeled heterodimeric peptide BBN-RGD radiotracer was designed to identify tumors at all PC stages by binding to the target receptors or biomarkers in primary tumors, metastatic lymph nodes, and metastatic bone lesions.

The radioactive atoms enable positron emission tomography (PET) or single photon emission computed tomography (SPECT) scanners to image the areas where the tracers have collected in large numbers. In a Phase I clinical trial in 13 PC patients, the tracer was able to successfully identify three of four primary tumors, all 14 metastatic lymph nodes and, significantly, was also able to identity all 20 of the metastatic bone lesions. In contrast, only two of the primary tumors, five lymph nodes, and 12 bone lesions were positive using the 68Ga-BBN single receptor tracer. The study was published in the February 2017 issue of The Journal of Nuclear Medicine.

“We are far from finding one method to diagnose and monitor prostate cancer, but this is a step in that direction. Targeting multiple biomarkers could potentially allow us to identify prostate cancer at its early stages as well as after metastasis in one scan,” said senior author Xiaoyuan Chen, PhD, chief of the laboratory of molecular imaging and nanomedicine at NIBIB. “Dual-receptor targeting tracers could one day be the primary method for diagnosing and monitoring prostate cancer, reducing the amount of medical scans a patient would be forced to undergo and streamlining the diagnostic and therapeutic process.”

A variety of imaging techniques and tests are currently used to diagnose and monitor prostate cancer, including prostate specific antigen (PSA) blood tests, magnetic resonance imaging (MRI), PET and SPECT, and computerized tomography (CT) scans. Each method has strengths and weaknesses, but there is no single method that is able to successfully identify and monitor primary tumors, metastatic lymph nodes, and bone lesions, which can cause the patient to undergo unnecessary treatments or painful biopsies.

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Dose Area Product Meter
VacuDAP
New
DR Flat Panel Detector
1500L
Laptop Ultrasound Scanner
PL-3018

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.